Spyre Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
88.1M
on 2026-06-30, from 36.6M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-06-26. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗
$500.0M
TD Securities (USA), agreement of 2026-06-26. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Cash
21.9 quarters
$1.15B on 2026-06-30 ÷ $52.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-04-16 | Public offering | 6,500,000 | $62.00 | $403.0M | 424B5 ↗ |